Revise laws related to healthcare utilization review
Summary
SB 446 revises Montana’s health utilization review laws to require that certain insurance utilization review decisions be made or reviewed by physicians licensed in the state. For adverse determinations, the bill requires the physician to hold an unrestricted Montana medical license, have a specialty focused on the condition being reviewed, and act under the clinical direction of a state-licensed medical director. For grievance reviews, the bill similarly requires a physician with the appropriate specialty and experience, and bars participation by a physician who was directly involved in the original denial or who has a financial interest in the outcome.
The bill also creates an automatic-approval remedy: if a health insurance issuer or its contracted utilization review organization fails to comply with the specified review requirements, the health care service under review is deemed authorized. In addition, SB 446 amends Montana’s prior-authorization statute for prescription drugs by limiting when prior authorization may be required for certain categories, including stable generic drugs, drugs previously approved for therapeutic duplication, dosage adjustments within approved or clinically consistent ranges, FDA-approved substance use disorder medications, and long-acting injectable antipsychotics. It also requires physician involvement in adverse determinations for prescription drug prior authorization when a denial is issued.
Impact
SB 446 would amend and expand Montana’s insurance utilization review and prior-authorization framework in Title 33, chapter 32, by imposing physician-specific qualifications on adverse determinations and grievance reviews and by adding an automatic approval consequence for noncompliance. It would directly affect health insurance issuers, utilization review organizations, medical directors, and physicians involved in utilization management, while also limiting insurer discretion over certain prescription drug prior authorizations. The bill’s changes are intended to strengthen clinical oversight and reduce administrative denials in health coverage decisions.
Sentiment
The voting record suggests broad overall support for the bill, with strong majorities in both chambers and unanimous or near-unanimous votes on several later stages, including final adoption of the free conference committee report. Earlier votes show some opposition and procedural resistance, including a failed motion to table and a narrower Senate passage on second reading, indicating that the bill was not entirely uncontroversial. Still, the final outcome reflects a generally favorable legislative sentiment toward the measure.
Contention
The main points of contention appear to have centered on the bill’s impact on insurer utilization review authority and the automatic-approval penalty for noncompliance. Opponents likely viewed the physician-only requirements and specialty matching rules as more restrictive and potentially burdensome for insurers and utilization review organizations, while supporters likely argued that medical decisions should be made by appropriately qualified physicians and that patients should not be delayed or denied care because of procedural failures. The conference process and the Senate’s initial refusal to concur with House amendments indicate that the details of the physician-review requirements and related enforcement provisions were the most disputed aspects.